浙江医药股份有限公司2025年半年度报告摘要

Group 1 - The core viewpoint of the announcements is the approval of the 2025 semi-annual report and the election of key board members [4][6][8] - The board meeting was held on August 25, 2025, with all twelve directors participating, ensuring compliance with legal and regulatory requirements [3] - The semi-annual report was approved unanimously with 12 votes in favor, indicating strong board support for the company's financial disclosures [4][7] Group 2 - The company confirmed that there are no significant changes in its operational situation during the reporting period [1] - The board of directors guarantees the truthfulness, accuracy, and completeness of the announcements, taking legal responsibility for the content [2]